Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Johann S. de Bono(Royal Marsden NHS Foundation Trust), Mark N. Stein(Cornell University), David I. Quinn(USC Norris Comprehensive Cancer Center), Daniel M. Geynisman(Fox Chase Cancer Center), Kevin D. Courtney(The University of Texas Southwestern Medical Center), Tomasz M. Beer(Exact Sciences (United States)), Yifah Yaron, Howard A. Burris(Deaconess Hospital), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), David James VanderWeele(Northwestern University), James Strauss(Texas Oncology), Xīn Gào(Qingdao University), Che‐Leung Law(Seagen (United States))
Cited by 36
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k